Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor positive breast cancer (ANZ0501 LATER): An open-label randomised controlled trial

Postmenopausal women who had completed at least 4 years of any standard endocrine therapy, at least one year prior, were randomised to observation or 5 years of letrozole 2.5mg daily. At a median of 3.9 years of follow-up, 2/181 (1.1%) patients allocated letrozole experienced an invasive breast cancer event, compared with 17/179 (9.5%) patients allocated to observation (P=0.0004). This suggests a potential benefit to reintroduction of letrozole in this setting.

from Cancer via ola Kala on Inoreader http://ift.tt/1PVP9lr
via IFTTT